Advanced biliary tract cancer at ASCO 2024

CE / CME

Targeted Therapies in Advanced Biliary Tract Cancer: Practical Strategies in a Changing Therapeutic Landscape

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.25 Medical Knowledge MOC points

Released: June 17, 2024

Expiration: June 16, 2025

Mitesh J. Borad
Mitesh J. Borad, MD
Lipika Goyal
Lipika Goyal, MD, MPhil
James J. Harding
James J. Harding, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Presurvey 1: Which of the following actionable alterations occur frequently in ICC (>10%) AND should be assessed in all patients with advanced ICC, with results influencing targeted therapy decisions?​

2.

Presurvey 2: Which of the following agents is an MDM2 inhibitor with an ongoing phase II study onto which patients with advanced TP53-WT, MDM2-amplified BTC could be enrolled?

3.

  • 37-yr-old female with iCCA; underwent resection and 6 mo of adjuvant therapy but experiences recurrence 18 mo later

  • PD with gemcitabine + cisplatin

  • Tumor molecular profiling: FGFR2-POC1B fusion, MSS

Presurvey 3: In your current practice, which of the following treatments would you recommend for this patient?